Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
59.89
87.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Shenzhen New Industries Biomedical Engineering Co Ltd stock under the Base Case scenario is 86.51 CNY. Compared to the current market price of 61.88 CNY, Shenzhen New Industries Biomedical Engineering Co Ltd is Undervalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Shenzhen New Industries Biomedical Engineering Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Shenzhen New Industries Biomedical Engineering Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Shenzhen New Industries Biomedical Engineering Co Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIB) stands at the forefront of innovation in the biomedical sector, specializing in the development and manufacturing of cutting-edge medical devices and diagnostic solutions. Founded in a thriving economic hub, Shenzhen, the company harnesses state-of-the-art technology and research expertise to deliver products that enhance healthcare outcomes. With a robust portfolio that spans various therapeutic areas, including critical care, cardiology, and infectious diseases, SNIB is not only committed to advancing healthcare but also to addressing pressing global health challenges. Their dedication to research and development, coupled with...
Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIB) stands at the forefront of innovation in the biomedical sector, specializing in the development and manufacturing of cutting-edge medical devices and diagnostic solutions. Founded in a thriving economic hub, Shenzhen, the company harnesses state-of-the-art technology and research expertise to deliver products that enhance healthcare outcomes. With a robust portfolio that spans various therapeutic areas, including critical care, cardiology, and infectious diseases, SNIB is not only committed to advancing healthcare but also to addressing pressing global health challenges. Their dedication to research and development, coupled with strategic partnerships with leading research institutions, positions them as a significant player in the rapidly expanding biomedical market.
For investors, SNIB represents a compelling opportunity driven by a combination of strong growth potential and strategic ambition. The company has consistently demonstrated impressive revenue growth, complemented by a commitment to innovation, which has resulted in a growing pipeline of products that meet both current and emerging healthcare needs. With the rising demand for advanced medical solutions globally, SNIB is poised to leverage its technological strengths and market position to capture an increasing share of this burgeoning industry. Additionally, the company's proactive approach to regulatory compliance and quality assurance underscores its commitment to delivering safe and effective products, further enhancing investor confidence in its long-term viability and success.
Shenzhen New Industries Biomedical Engineering Co., Ltd., often referred to as New Industries Biomedical, focuses on several core business segments within the biomedical field. These segments typically include:
-
Medical Devices: The company designs and manufactures a range of medical devices that contribute to diagnostic and therapeutic practices. This may encompass products for monitoring patient health, surgical tools, and instruments used in various medical procedures.
-
In Vitro Diagnostic (IVD) Products: A significant segment involves the development of IVD products, which are essential for conducting tests on samples taken from the human body, such as blood or urine. This includes reagents, diagnostic kits, and machines used in laboratories for disease detection and monitoring.
-
Biotechnology Research and Development: New Industries Biomedical may engage in R&D activities to innovate and improve existing biomedical technologies. This could focus on areas such as biomaterials, genetic engineering, or cell therapy, reflecting ongoing advancements in healthcare technology.
-
Health Management and Services: The company could offer solutions that integrate health management systems, possibly including software that assists healthcare providers in managing patient data, improving workflow efficiencies, and enhancing patient care through analytics.
-
Laboratory Equipment: Manufacturing and supplying laboratory equipment necessary for conducting research and clinical trials. This might include centrifuges, incubators, and other essential analytical tools for biomedical research and applications.
-
Consulting and Training Services: Providing consulting services to healthcare institutions on the implementation and usage of their products and technologies, along with training for medical personnel on the latest diagnostics and treatment methodologies.
By focusing on these core segments, Shenzhen New Industries Biomedical aims to improve healthcare outcomes through innovative technological solutions and a commitment to research and development.
Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) possesses several competitive advantages that help it stand out in the biomedical engineering sector, particularly in the field of in vitro diagnostics (IVD). Here are some key advantages:
-
Innovative Technology: SNIBE invests heavily in R&D, focusing on developing advanced diagnostic technologies and products, which can lead to superior accuracy and efficiency in testing.
-
Comprehensive Product Line: The company offers a wide range of products, including automated analyzers and a variety of reagents, which allows it to cater to diverse customer needs and establish itself as a one-stop-shop in the IVD market.
-
Strong Intellectual Property: SNIBE has developed a robust portfolio of patents and proprietary technologies, which provide a barrier to entry for competitors and enhance its market position.
-
Global Reach: By establishing international partnerships and expanding its distribution networks, SNIBE is able to penetrate foreign markets, diversifying its revenue streams and mitigating regional risks.
-
Cost Leadership: The company often produces high-quality products at competitive prices, allowing it to capture market share in both developed and emerging markets.
-
Regulatory Expertise: Strong knowledge and experience in navigating regulatory environments enable SNIBE to expedite the approval process for new products, enhancing its speed to market.
-
Strong Customer Relationships: Building long-term relationships with healthcare institutions and laboratories aids in customer loyalty and provides insights into market needs, allowing for better product development.
-
Focus on Quality Control: A commitment to high standards of quality management can help SNIBE maintain a strong reputation and trust within the industry, critical for products that impact health outcomes.
-
Adaptability and Agility: Being in a rapidly changing technological landscape, SNIBE’s ability to quickly adapt to new market demands and technological advancements is a significant advantage.
These factors combined position Shenzhen New Industries Biomedical Engineering as a formidable player in the biomedical sector, allowing it to compete effectively against rivals.
Shenzhen New Industries Biomedical Engineering Co., Ltd., like many companies in the biomedical and healthcare industry, faces several risks and challenges that could impact its operations and growth. Here are some potential risks and challenges:
-
Regulatory Compliance: The biomedical industry is heavily regulated. Stricter regulations, changes in compliance requirements, or delays in obtaining necessary approvals for new products can hinder progress.
-
Market Competition: The biomedical field is highly competitive, with numerous players constantly entering the market. The company must innovate and differentiate its products to maintain or gain market share.
-
Technological Advancement: Rapid advancements in technology require continuous investment in research and development. Failure to keep up can result in obsolescence and loss of competitive advantage.
-
Supply Chain Disruptions: Global supply chain issues, particularly in the wake of events like the COVID-19 pandemic, can affect the availability and cost of raw materials and components crucial for biomedical products.
-
Intellectual Property Risks: There is a risk of patent infringement or challenges related to intellectual property rights, which can lead to costly legal battles and potential disruptions in product launches.
-
Quality Control and Product Recalls: Maintaining high-quality standards is critical. Any lapses can result in product recalls, lawsuits, and damage to the company’s reputation.
-
Cybersecurity Threats: As the company likely utilizes advanced technology and data systems, it is susceptible to cyberattacks that could compromise sensitive data or disrupt operations.
-
Economic Factors: Fluctuations in the economy, including changes in healthcare funding, reimbursement rates, and consumer spending, can impact sales and profitability.
-
Talent Acquisition and Retention: The company may face challenges in attracting and retaining skilled professionals needed for its operations, especially in specialized fields such as biomedical engineering and research.
-
Geopolitical Risks: Tensions in international trade and relationships can impact the company's operations, particularly if it relies on global suppliers or markets.
-
Public Perception and Trust: Trust in biomedical companies can fluctuate based on public perceptions of safety and efficacy. Negative publicity or controversies related to product safety could impact the company’s reputation and sales.
Navigating these risks will require strategic planning, efficient operations, and a focus on innovation and compliance.
Revenue & Expenses Breakdown
Shenzhen New Industries Biomedical Engineering Co Ltd
Balance Sheet Decomposition
Shenzhen New Industries Biomedical Engineering Co Ltd
Current Assets | 4.7B |
Cash & Short-Term Investments | 2.8B |
Receivables | 954.1m |
Other Current Assets | 978.8m |
Non-Current Assets | 3.7B |
Long-Term Investments | 1.4B |
PP&E | 1.5B |
Intangibles | 165.5m |
Other Non-Current Assets | 560.3m |
Current Liabilities | 606.1m |
Accounts Payable | 222.5m |
Accrued Liabilities | 148.1m |
Other Current Liabilities | 235.5m |
Non-Current Liabilities | 91.4m |
Long-Term Debt | 3.2m |
Other Non-Current Liabilities | 88.3m |
Earnings Waterfall
Shenzhen New Industries Biomedical Engineering Co Ltd
Revenue
|
4.3B
CNY
|
Cost of Revenue
|
-1.1B
CNY
|
Gross Profit
|
3.1B
CNY
|
Operating Expenses
|
-1.1B
CNY
|
Operating Income
|
2B
CNY
|
Other Expenses
|
-177.5m
CNY
|
Net Income
|
1.8B
CNY
|
Free Cash Flow Analysis
Shenzhen New Industries Biomedical Engineering Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Shenzhen New Industries Biomedical Engineering Co Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
Score
Shenzhen New Industries Biomedical Engineering Co Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shenzhen New Industries Biomedical Engineering Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Shenzhen New Industries Biomedical Engineering Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shenzhen New Industries Biomedical Engineering Co Ltd
According to Wall Street analysts, the average 1-year price target for Shenzhen New Industries Biomedical Engineering Co Ltd is 88.27 CNY with a low forecast of 77.44 CNY and a high forecast of 100.58 CNY.
Dividends
Current shareholder yield for Shenzhen New Industries Biomedical Engineering Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The company is headquartered in Shenzhen, Guangdong and currently employs 2,298 full-time employees. The company went IPO on 2020-05-12. The firm operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The firm sells its products both in domestic and international markets, including Asia, Europe, America and Africa.
Contact
IPO
Employees
Officers
The intrinsic value of one Shenzhen New Industries Biomedical Engineering Co Ltd stock under the Base Case scenario is 86.51 CNY.
Compared to the current market price of 61.88 CNY, Shenzhen New Industries Biomedical Engineering Co Ltd is Undervalued by 28%.